Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217912 · ClinicalTrials.gov registry record · Phase 2
Daridorexant to Prevent Post-cardiotomy Delirium
A Phase 2 study of Postoperative Delirium and Postoperative Cognitive Decline, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07217912 is a Phase 2 study of Postoperative Delirium and Postoperative Cognitive Decline that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 80 participants, below the 170-participant average among 6 other Postoperative Delirium trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07217912, a Phase 2 study of Postoperative Delirium and Postoperative Cognitive Decline, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this follow-on pilot randomized clinical trial is to obtain additional preliminary data to inform a larger, adequately powered phase 2b trial of daridorexant for the prevention of postoperative delirium after heart surgery. Having demonstrated feasibility in a prior study (RSRB #9841), this study aims to estimate the effect of daridorexant on (1) reducing delirium symptom burden and incidence and (2) improving self-reported sleep quality during the postoperative period, and (3) to assess the feasibility of collecting objective sleep data in the postoperative setting. Participants will: complete a baseline visit; take the study drug, either daridorexant or placebo, each of the first three nights after heart surgery; and be evaluated daily for sleep and delirium during the first three postoperative days. Participants will also have the option of wearing a sleep monitor in the hospital each of the first three nights after surgery.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Daridorexant 50 mg
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07217912
The ClinicalTrials.gov registry entry for NCT07217912 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 6 other Postoperative Delirium trials with a reported enrollment target (53% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Postoperative Delirium appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07217912 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07217912 about?
NCT07217912 is a clinical study titled "Daridorexant to Prevent Post-cardiotomy Delirium". The goal of this follow-on pilot randomized clinical trial is to obtain additional preliminary data to inform a larger, adequately powered phase 2b trial of daridorexant for the prevention of postoperative delirium after heart surgery. Having demonstrated feasibility in a prior study (RSRB #9841), t...
What is the current status of trial NCT07217912?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-10-14. Estimated completion is 2027-11-01.
What conditions does trial NCT07217912 study?
This clinical trial studies the following conditions: Postoperative Delirium, Postoperative Cognitive Decline.
What interventions are being tested in trial NCT07217912?
The interventions under investigation include: Placebo (OTHER), Daridorexant 50 mg (DRUG).
Who is sponsoring clinical trial NCT07217912?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217912 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Delirium
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study
RECRUITING · Phase 2
-
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
RECRUITING · Phase 3
-
Digital Sleep Optimization for Brain Health Outcomes in Older Surgical Patients
RECRUITING · NA
-
CEReBral AutorEgulation in Non-cardiac SuRgery and Relationship to Postoperative DeliriUm State
RECRUITING
-
Efficacy of Suvorexant on Post-operative Sleep Disturbance
RECRUITING · Phase 4
-
Building a Platform for Precision Anesthesia in the Geriatric Surgical Patient
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.